Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
YuanMing Capital is a healthcare specialty fund focusing on China-US cross border investments with offices in Beijing and New York City. The investment team has rich industry experience and a successful investment track record. The fund invests in therapeutics, medical devices, diagnostics as well as healthcare service companies based in US and/or China. We seek to bring capital and strategic resources to the future leaders of the industry.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
7/2018 | Ascentage Pharma | Series C | 150M |
12/2016 | Ascentage Pharma | Series B | 0 |
5/2017 | CANbridge Pharmaceuticals | Series B | 25M |
7/2020 | CF PharmTech | Series F | 50.9M |
6/2018 | Mevion Medical Systems | Private Equity Round | 150M |
3/2018 | JW Therapeutics | Series A | 0 |
8/2014 | Mevion Medical Systems | Private Equity Round | 0 |
1/2016 | aptX | Series A | 20M |
8/2015 | Ascentage Pharma | Series A | 15.5M |
5/2018 | Ansun BioPharma | Series A | 85M |
6/2018 | Adlai Nortye | Series B | 53M |
2/2020 | CANbridge Pharmaceuticals | Series D | 98M |
7/2020 | CF PharmTech | Series F | 0 |
2/2020 | CANbridge Pharmaceuticals | Series D | 0 |
7/2018 | Ascentage Pharma | Series C | 0 |
6/2018 | Adlai Nortye | Series B | 0 |
6/2018 | Mevion Medical Systems | Private Equity Round | 0 |
5/2018 | Ansun BioPharma | Series A | 0 |
3/2018 | JW Therapeutics | Series A | 0 |
5/2017 | CANbridge Pharmaceuticals | Series B | 0 |
12/2016 | Ascentage Pharma | Series B | 0 |
1/2016 | aptX | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|